China considers mixing vaccines to bolster efficacy - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
新型冠状病毒

China considers mixing vaccines to bolster efficacy

Disease control centre makes first public admission that there are efficacy problems with domestic jabs
00:00

{"text":[[{"start":13.61,"text":"The Chinese Center for Disease Control and Prevention has raised the prospect of mixing vaccines and varying doses to boost efficacy, the first time a government body has acknowledged concerns over the effectiveness of homegrown jabs. "}],[{"start":28.93,"text":"Gao Fu, CDC head, told a conference on Saturday that the agency was “considering how to solve the problem that the efficacy of existing vaccines is not high”, according to local media. "},{"start":40.984,"text":"Gao proposed mixing different vaccines as well as amending the sequence of doses, such as changing the number and quantity of doses, and the interval between them. "}],[{"start":51.739999999999995,"text":"Any new strategy will have ramifications for the more than 20 countries that China said it was supplying in mostly bilateral “vaccine diplomacy” deals. "}],[{"start":61.66,"text":"As of March, China had supplied 40m doses to countries across the globe, including Brazil, Serbia and the United Arab Emirates, prompting the US and its allies to launch their own drive to supply 1bn doses of Johnson & Johnson’s Covid-19 vaccine to south-east Asian nations. "}],[{"start":81.38,"text":"Chile, which has relied on China’s Sinovac vaccine for its inoculation campaign, is in the midst of another Covid-19 wave from new variants. "},{"start":90.984,"text":"The country has administered 62 doses per 100 residents, according to the Financial Times vaccine tracker, the third-highest rate in the world. "}],[{"start":100.88,"text":"A recent study of the effectiveness of Chile’s vaccination programme found the efficacy of a single dose of the Sinovac jab was just 3 per cent, compared with 56 per cent with two shots. "},{"start":113.109,"text":"However, local health experts have not linked the latest wave to the vaccine’s efficacy rate. "}],[{"start":120.19999999999999,"text":"Social-media posts on Gao’s remarks were swiftly censored, according to Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations. "}],[{"start":131.1,"text":"“It is the first time . . . a government official publicly admitted that the protection rate is a concern in the vaccination drive,” Huang added. "},{"start":139.47899999999998,"text":"China had administered 65m doses across the country by the middle of March. "}],[{"start":145.60999999999999,"text":"Unlike other vaccine producers, China’s manufacturers have not published their phase 3 trial data, leading to accusations of a lack of transparency over the vaccine’s effectiveness on different groups. "}],[{"start":158.85999999999999,"text":"For now, the main jabs approved for use in China are the traditional “inactivated virus” vaccines produced by Sinopharm, Sinovac and other domestic groups. "}],[{"start":169.94,"text":"Sinopharm claims a 79 per cent efficacy rate, similar to those achieved by AstraZeneca in its US trials. "},{"start":178.232,"text":"However, while AstraZeneca revised down its rates after facing criticism for releasing incomplete data, neither Sinopharm nor any of its Chinese peers have released phase 3 data for public scrutiny. "}],[{"start":193.07999999999998,"text":"Peter English, a retired communicable disease control consultant at Public Health England, said it was “astonishing” that phase 3 trial data for the Chinese vaccines had not yet been published. "}],[{"start":205.82999999999998,"text":"“We have little information on how effective these vaccines are,” he said, adding efficacy data against variants of concern was needed. "},{"start":214.68399999999997,"text":"Still, English said it was “interesting” that China was considering mixing and matching vaccines after moves from France and Germany to do so following safety concerns about the Oxford/AstraZeneca shot. "}],[{"start":227.89999999999998,"text":"Sinovac Biotech’s CoronaVac vaccine has an overall efficacy rate of 51 per cent among people aged between 18 and 60, according to documents published by a Hong Kong panel of experts. "}],[{"start":241.45999999999998,"text":"However, CoronaVac phase 1 and 2 data published in The Lancet found the shots were “safe and well tolerated”. "}],[{"start":249.89,"text":"Gao also warned that reopening China’s borders to foreigners, who have been barred from entering the country since March last year, posed a risk to elderly people, who have not yet been vaccinated. "}],[{"start":262.69,"text":"The timing of relaxing border restrictions will affect attendees at Beijing’s Winter Olympic Games in February 2022. "}],[{"start":271.6,"text":"Additional reporting by Donato Mancini in Rome "}],[{"start":275.12,"text":""}]],"url":"https://creatives.ftacademy.cn/album/001092107-1618190844.mp3"}

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

若特朗普“撤退”,欧洲防务集团能否挺身而出?

欧洲的军工企业近来一直在飞速发展,而美国总统的做法可能会加快它们的崛起。

默茨“不计代价”的支出努力有望结束德国多年的增长停滞

柏林墙倒塌以来最大规模的经济刺激,可能助推欧洲最大经济体恢复疫情前的增长趋势。

北美管道公司警告特朗普关税将冲击燃料价格

TC Energy的首席执行官在接受FT采访时表示,北美大陆需要深化跨境管道连接,以避免通胀并保护能源安全。

美国经济增长面临的威胁有多严重?

特朗普誓言“松绑”美国经济,但在总统对国会发表的乐观言论之下,是对经济增长日益增加的担忧。

Lex专栏:贝莱德的巴拿马交易反映其战略转变

管理持有少量公共债务和股权的基金变得没那么有趣了,这也是特朗普的功劳。

特朗普为何想得到乌克兰的稀土?

稀土在一系列产业中得到广泛使用,包括对国家安全至关重要的行业,而中国在稀土领域占主导地位。
设置字号×
最小
较小
默认
较大
最大
分享×